Alfusozine treatment of prostatic adenoma: efficacy in relation to sexuality
- Authors: Kogan MI1, Kireev AY.1, Kogan MI1, Kireev AY.1
-
Affiliations:
- Issue: No 1 (2011)
- Pages: 28-31
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279005
- ID: 279005
Cite item
Full Text
Abstract
Blood levels of total PSA and testosterone, size of the prostatic gland, Qmax were measured in 40 patients with prostatic adenoma symptoms treated with alfusozine in a dose 10 mg/day before the treatment, on the treatment week 4, 12 and 24. At the same time the examinees were questioned using IPSS, MSHQ, IIEF questionnaires. The sexuality phenotype was estimated according to the Rostov Questionnaire of Integral Male Sexuality. It was found that sexuality phenotypes (hypo-, normo- and hypersexuality) occur with the same frequency in males with prostatic adenoma symptoms. Hypersexual men with prostatic adenoma have more definite lower urinary tract symptoms, worse erection and ejaculation, more frequent signs of hypogonadism. The highest alfusozine efficacy was observed in normo- and hyposexual men with prostatic adenoma who achieved better results in improvement of Qmax, symptoms of the lower urinary tract, erectile and ejaculation function. The treatment efficacy in the hypersexual men is low.
References
- Аль-Шукри С. Х., Корнеев И. А. Сексуальная функция у мужчин с сопутствующими урологическими заболеваниями. Урология 2005; 3: 18-22.
- Аль-Шукри С. Х., Журавлев В. Н., Коган М. И. и др. Исследование сексуальной функции пациентов с доброкачественной гиперплазией предстательной железы при лечении альфузозином. Рус. мед. журн. 2008; 16: 1997-2002.
- O'Leary M. P. Quality of life and sexuality: Methodological aspects. Eur. Urol. 2001; 40: 13-18.
- Sak S. C., Eardley I. What is the relationship between benign prostatic hyperplasia and sexual function? Sex. Relationship Ther. 2004; 19 (4): 431-443.
- Schulman C. Impact of treatment of BPH on sexuality. Prostate Canc. Prost. Dis. 2001; 4 (1): 12-16.
- Daly M. P. Quality of life in sexually active men with symptomatic benign prostatic hyperplasia. Effects of treatment. Clin. Drug Invest. 2005; 25 (4): 219-230.
- Аполихин О. И., Абдуллин И. И. Необходимость использования доказательной медицины в принятии клинических решений на примере эректильной дисфункции. Урология 2003; 3: 3-7.
- Rosen R. C., Riley A. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
- Rosen R. C., Catania J. et al. Male sexual health questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777-782.
- Rosen R., Altwein J., Boyle P. et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-649.
- Rosen R. C., Seftel A., Roehrborn C. G. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int. J. Impot. Res. 2007; 19: 480-485.
- Rosen R. C., Fitzpatrick J. M. Alfuzosin 10 mg once daily improves ejaculatory dysfunction in real life practice: Results of a 6-month study in 1681 men with LUTS suggestive of BPH. Br. J. Urol. Int. 2009; 104: 974-983.
- Коган М. И., Киреев А. Ю. Анкета интегральной оценки мужской сексуальности. Урология 2009; 1: 46-50.
- Киреев А. Ю. О взаимосвязи мужской сексуальности с развитием и течением доброкачественной гиперплазии предстательной железы: Дис. ... канд. мед. наук. Ростов-н/Д; 2009.
- Коган М. И., Киреев А. Ю. Сексуальность мужчины и развитие доброкачественной гиперплазии простаты. Consilium Medicum 2009; 11 (7): 75-79.
- Коган М. И., Киреев А. Ю. Различия уровней тестостерона и полиморфизма гена андрогенового рецептора у пациентов с симптомной доброкачественной гиперплазией простаты в зависимости от сексуальной активности. Андрол. и генитал. хир. 2009; 2: 118.
Supplementary files
